Biliary tract cancer

HER2-Positivity in Advanced Biliary Tract Cancer: A Dual Role as a Negative Prognostic Factor and a Potent Therapeutic Vulnerability

By MedXY 01/13/2026

A multi-institutional analysis reveals that HER2-positivity in advanced biliary tract cancer signals a poorer prognosis but offers a significant survival benefit when targeted with anti-HER2 therapies, advocating for routine screening and standardized diagnostic criteria.

Gastroenterology news Oncology

Preserving the Immune Reservoir: Why Excessive Lymph Node Dissection Hinders Immunotherapy in Recurrent Biliary Tract Cancer

By MedXY 01/11/2026

A multi-center study reveals that extensive dissection of non-metastatic tumor-draining lymph nodes reduces immunotherapy efficacy in recurrent biliary tract cancer by depleting crucial reservoirs of memory T cells and dendritic cells.

news Oncology

Zanidatamab Shows Durable Activity and Pain Benefit in HER2‑Positive Metastatic Biliary Tract Cancer: Final HERIZON‑BTC‑01 Results

By MedXY 11/24/2025

Final HERIZON‑BTC‑01 data show zanidatamab induces durable responses and a median overall survival of 15.5 months in previously treated HER2‑overexpressing metastatic biliary tract cancer, with greatest benefit in IHC 3+ tumors and manageable toxicity.

news Oncology

Harnessing Immune-Checkpoint Inhibitors in Biliary Tract Cancer: Current Benefits and Future Perspectives

By MedXY 10/29/2025

Immune-checkpoint inhibitors combined with chemotherapy have redefined treatment for advanced biliary tract cancer, offering improved survival despite challenges posed by tumor heterogeneity and biomarker limitations. Ongoing research explores novel combinations and earlier stage interventions to optimize patient outcomes.

Gastroenterology news Oncology

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: A 3-Year Survival Update from the Phase III TOPAZ-1 Study

By MedXY 10/29/2025

The TOPAZ-1 study shows durvalumab combined with gemcitabine and cisplatin improves 3-year overall survival in advanced biliary tract cancer with manageable safety, establishing a new standard of care.

Gastroenterology news Oncology

Evaluating Surrogate Endpoints in Advanced Biliary Tract Cancer: Progression-Free Survival Outperforms Response Rates as a Predictor of Overall Survival

By MedXY 10/28/2025

This comprehensive analysis reveals that progression-free survival moderately correlates with overall survival in advanced biliary tract cancer, while objective response and disease control rates show poor correlation, underscoring the need for better surrogate markers in clinical trials.

Gastroenterology news Oncology

Conversion Therapy with Tislelizumab, Lenvatinib, and GEMOX in Unresectable Locally Advanced Biliary Tract Cancer: The ZSAB-TransGOLP Phase 2 Study

By MedXY 10/15/2025

The ZSAB-TransGOLP study demonstrates the promising efficacy and manageable safety of combining tislelizumab, lenvatinib, and GEMOX chemotherapy as a conversion therapy for unresectable locally advanced biliary tract cancer, achieving a 63% R0 resection rate.

Clinical Updates news Oncology Specialties

Evaluating the Addition of Polymeric Micellar Paclitaxel to Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: Insights from a Phase 3 Randomized Clinical Trial

By MedXY 10/01/2025

A South Korean phase 3 trial found that adding polymeric micellar paclitaxel to gemcitabine and cisplatin did not improve survival for advanced biliary tract cancer, highlighting the challenges of intensified chemotherapy regimens.

Clinical Updates news Oncology

Maintaining Quality of Life While Extending Survival: HRQoL Outcomes from KEYNOTE-966 in Advanced Biliary Tract Cancer

By MedXY 09/20/2025

The KEYNOTE-966 trial demonstrates that adding pembrolizumab to gemcitabine and cisplatin improves overall survival in advanced biliary tract cancer patients without compromising health-related quality of life.

Clinical Updates news Oncology

Efficacy of Liposomal Irinotecan Plus 5-FU/LV in Previously Treated Biliary Tract Cancer: Insights from Pooled NIFTY and NALIRICC Trials

By MedXY 09/20/2025

A pooled analysis of NIFTY and NALIRICC trials demonstrates that liposomal irinotecan combined with 5-FU/leucovorin significantly improves progression-free survival and response rates in previously treated biliary tract cancer, with notable ethnic variations in toxicity profiles.

news Oncology Public Health Specialties

International Trends in Biliary Tract Cancer Mortality from 2000 to 2022: A Comprehensive WHO Database Analysis

By MedXY 08/25/2025

This observational study reveals stable global biliary tract cancer mortality rates over two decades, with a striking rise in intrahepatic cholangiocarcinoma mortality, underscoring the need for targeted screening and management strategies.